Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free NFX Stock Alerts

Nuformix (NFX) Competitors

Nuformix logo
GBX 0.14 +0.01 (+6.20%)
As of 05:04 AM Eastern
Compare

NFX vs. CLBX, NSCI, FAB, GENF, and SNG

Should you buy Nuformix stock or one of its competitors? Nuformix's main competitors and comparable companies include Cellbxhealth (CLBX), NetScientific (NSCI), Fusion Antibodies (FAB), Genflow Biosciences (GENF), and Synairgen (SNG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nuformix compare to Cellbxhealth?

Cellbxhealth (LON:CLBX) and Nuformix (LON:NFX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Cellbxhealth's return on equity of 0.00% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
Nuformix N/A -83.53%-17.20%

In the previous week, Cellbxhealth's average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
Cellbxhealth Neutral
Nuformix Neutral

Cellbxhealth has higher revenue and earnings than Nuformix. Nuformix is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M13.48N/A-£3.49N/A
NuformixN/AN/A-£383.40K-£0.03N/A

0.4% of Cellbxhealth shares are held by institutional investors. Comparatively, 0.1% of Nuformix shares are held by institutional investors. 1.2% of Cellbxhealth shares are held by insiders. Comparatively, 7.5% of Nuformix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Cellbxhealth beats Nuformix on 5 of the 7 factors compared between the two stocks.

How does Nuformix compare to NetScientific?

Nuformix (LON:NFX) and NetScientific (LON:NSCI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Nuformix has higher earnings, but lower revenue than NetScientific. Nuformix is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuformixN/AN/A-£383.40K-£0.03N/A
NetScientific£1.45M0.00-£2.64M-£0.11N/A

0.1% of Nuformix shares are owned by institutional investors. Comparatively, 14.7% of NetScientific shares are owned by institutional investors. 7.5% of Nuformix shares are owned by company insiders. Comparatively, 42.4% of NetScientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Nuformix has a beta of 1.519, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, NetScientific has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market.

In the previous week, Nuformix's average media sentiment score of 0.00 equaled NetScientific'saverage media sentiment score.

Company Overall Sentiment
Nuformix Neutral
NetScientific Neutral

Nuformix has a net margin of 0.00% compared to NetScientific's net margin of -182.91%. NetScientific's return on equity of -13.70% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
NuformixN/A -83.53% -17.20%
NetScientific -182.91%-13.70%-9.42%

Summary

NetScientific beats Nuformix on 6 of the 10 factors compared between the two stocks.

How does Nuformix compare to Fusion Antibodies?

Fusion Antibodies (LON:FAB) and Nuformix (LON:NFX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
Nuformix Neutral

Nuformix has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Nuformix's return on equity of -83.53% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
Nuformix N/A -83.53%-17.20%

Nuformix has lower revenue, but higher earnings than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Nuformix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M8.47-£4.10M-£1.50N/A
NuformixN/AN/A-£383.40K-£0.03N/A

7.6% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 0.1% of Nuformix shares are owned by institutional investors. 5.9% of Fusion Antibodies shares are owned by insiders. Comparatively, 7.5% of Nuformix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Fusion Antibodies has a beta of 1.224, indicating that its share price is 22% more volatile than the broader market. Comparatively, Nuformix has a beta of 1.519, indicating that its share price is 52% more volatile than the broader market.

Summary

Nuformix beats Fusion Antibodies on 8 of the 10 factors compared between the two stocks.

How does Nuformix compare to Genflow Biosciences?

Genflow Biosciences (LON:GENF) and Nuformix (LON:NFX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Genflow Biosciences has a beta of 2.297, suggesting that its stock price is 130% more volatile than the broader market. Comparatively, Nuformix has a beta of 1.519, suggesting that its stock price is 52% more volatile than the broader market.

Genflow Biosciences is trading at a lower price-to-earnings ratio than Nuformix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
NuformixN/AN/A-£383.40K-£0.03N/A

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
Nuformix Neutral

Nuformix has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences-170.64% 332.06% -58.66%
Nuformix N/A -83.53%-17.20%

0.1% of Genflow Biosciences shares are owned by institutional investors. Comparatively, 0.1% of Nuformix shares are owned by institutional investors. 25.8% of Genflow Biosciences shares are owned by insiders. Comparatively, 7.5% of Nuformix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Nuformix beats Genflow Biosciences on 6 of the 9 factors compared between the two stocks.

How does Nuformix compare to Synairgen?

Nuformix (LON:NFX) and Synairgen (LON:SNG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Nuformix has a beta of 1.519, indicating that its share price is 52% more volatile than the broader market. Comparatively, Synairgen has a beta of -2.23, indicating that its share price is 323% less volatile than the broader market.

Nuformix is trading at a lower price-to-earnings ratio than Synairgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuformixN/AN/A-£383.40K-£0.03N/A
SynairgenN/AN/A-£15.86M-£1.66N/A

In the previous week, Nuformix's average media sentiment score of 0.00 equaled Synairgen'saverage media sentiment score.

Company Overall Sentiment
Nuformix Neutral
Synairgen Neutral

0.1% of Nuformix shares are owned by institutional investors. Comparatively, 30.7% of Synairgen shares are owned by institutional investors. 7.5% of Nuformix shares are owned by insiders. Comparatively, 3.2% of Synairgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Synairgen's return on equity of -51.06% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
NuformixN/A -83.53% -17.20%
Synairgen N/A -51.06%-30.58%

Summary

Nuformix beats Synairgen on 5 of the 8 factors compared between the two stocks.

Get Nuformix News Delivered to You Automatically

Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NFX vs. The Competition

Export
MetricNuformixBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£3.58M£3.74B£7.08B£2.89B
Dividend YieldN/A3.76%2.58%6.09%
P/E Ratio-4.6810.36268.52368.55
Price / SalesN/A1,269.22593.1683,653.78
Price / Cash3.55102.9470.5927.89
Price / Book0.2517.8213.147.23
Net Income-£383.40K-£13.23M£3.45B£5.89B
7 Day Performance6.20%2.97%1.82%1.19%
1 Month Performance-19.41%1.40%0.91%2.67%
1 Year PerformanceN/A55.37%67.70%69.88%

Nuformix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NFX
Nuformix
N/AGBX 0.14
+6.2%		N/A+55.4%£3.58MN/AN/A3
CLBX
Cellbxhealth
N/AGBX 1.33
-1.1%		N/AN/A£15.06M£1.15MN/AN/A
NSCI
NetScientific
N/AN/AN/AN/A£12.81M£1.45MN/A26
FAB
Fusion Antibodies
N/AGBX 9.70
-7.6%		N/A-28.0%£12.14M£1.60MN/A48
GENF
Genflow Biosciences
N/AGBX 1.86
-8.8%		N/A+236.6%£10.54MN/AN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:NFX) was last updated on 8/13/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel